All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2022-01-13T09:30:18.000Z

How do you incorporate MRD into treatment decision-making in clinical practice?

Jan 13, 2022
Share:

Bookmark this article

During Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?

How do you incorporate MRD into treatment decision-making in clinical practice?

Van Besien begins by discussing the complexities around the two major technologies we use to detect MRD, flow cytometry and molecular testing. He outlines reliable MRD tests, settings in which they can be used, and treatment options, such as MRD testing during induction for MPN1 mutated AML. He also describes the necessity for allogenic transplant consolidation in MRD- patients. Finally, he highlights the increasing data on maintenance therapy for patients that remain MRD+ e.g. TKI inhibitors.

 

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox